Suppr超能文献

观察性疫苗安全性研究中的信号揭示:以2型糖尿病为例。

Unmasking in an observational vaccine safety study: Using type 2 diabetes mellitus as an example.

作者信息

Ackerson Bradley K, Sy Lina S, Slezak Jeff, Chao Chun R, Hechter Rulin C, Takhar Harpreet S, Jacobsen Steven J

机构信息

Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Avenue, 2nd Floor, Pasadena, CA 91101, USA.

Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Avenue, 2nd Floor, Pasadena, CA 91101, USA.

出版信息

Vaccine. 2015 Nov 17;33(46):6224-6. doi: 10.1016/j.vaccine.2015.09.080. Epub 2015 Oct 9.

Abstract

BACKGROUND

In observational vaccine safety studies, diagnosis codes assigned prior to or on the day of vaccination (Day 0) are often excluded from analysis of safety signals since they usually represent pre-existing conditions. The limitations of this approach have been described for autoimmune conditions but not for other chronic conditions. We draw on our experience in a post-licensure quadrivalent human papillomavirus vaccine (HPV4) safety study to examine the effectiveness of exclusion of pre-existing and Day 0 diagnoses of type 2 diabetes mellitus (T2DM) in excluding prevalent T2DM.

METHODS

Subjects included all 117,402 females ages 9-26 years who received HPV4 August 2006-March 2008 in Kaiser Permanente Southern California. We identified potential incident T2DM cases using ICD9 code 250.xx associated with inpatient and emergency room visits during the 60 days following each HPV4 dose, excluding those with this code prior to their first HPV4 dose. Electronic medical records were reviewed to determine the dates of symptom onset, diagnostic labs, vaccine administration and T2DM diagnosis.

RESULTS

Of 33 potential incident T2DM cases identified using automated data, 4 (12%) were confirmed to have new onset T2DM after medical record review. Nineteen cases were excluded that did not have T2DM or had T2DM diagnosed before Day 0; nine had an abnormal fasting blood sugar (FBS) ordered on Day 0, prompting subsequent evaluation and diagnosis of T2DM; and one had elevated FBS and glucosuria prior to the first dose of HPV4 but T2DM diagnosed at a visit following vaccination.

CONCLUSION

These results suggest that among adolescents and young adults, the workup and subsequent diagnosis of pre-existing conditions may result from a visit at which a vaccination is administered. This "unmasking" phenomenon is not entirely eliminated by exclusion of pre-existing and Day 0 diagnoses. Medical record review should be considered in the evaluation of potential safety signals.

摘要

背景

在观察性疫苗安全性研究中,接种疫苗前或接种当天(第0天)分配的诊断代码通常在安全信号分析中被排除,因为它们通常代表预先存在的疾病。这种方法的局限性已针对自身免疫性疾病进行过描述,但尚未针对其他慢性病进行描述。我们借鉴在上市后四价人乳头瘤病毒疫苗(HPV4)安全性研究中的经验,以检验排除2型糖尿病(T2DM)预先存在的疾病和第0天诊断对于排除现患T2DM的有效性。

方法

研究对象包括2006年8月至2008年3月在南加州凯撒医疗机构接种HPV4的所有117402名9至26岁女性。我们使用与每次HPV4剂量后60天内住院和急诊就诊相关的ICD9代码250.xx识别潜在的新发T2DM病例,排除首次HPV4剂量之前有此代码的病例。查阅电子病历以确定症状发作日期、诊断实验室检查、疫苗接种和T2DM诊断日期。

结果

在使用自动化数据识别出的33例潜在新发T2DM病例中,4例(12%)经病历审查确认患有新发T2DM。19例病例被排除,其中没有T2DM或在第0天之前被诊断为T2DM;9例在第0天进行了空腹血糖(FBS)异常检查,随后促使对T2DM进行评估和诊断;1例在首次接种HPV4之前FBS和糖尿升高,但在接种疫苗后的一次就诊中被诊断为T2DM。

结论

这些结果表明,在青少年和年轻人中,对预先存在疾病的检查和随后的诊断可能源于接种疫苗的就诊。这种“揭露”现象不会因排除预先存在的疾病和第0天诊断而完全消除。在评估潜在安全信号时应考虑查阅病历。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验